The Japanese group pays $315m to co-develop an asset Vir got from a low-cost Sanofi deal.
ApexOnco Front Page
Recent articles
Solstice Oncology acquires porustobart from Harbour Biomed.
A work-stretched US FDA has several key approval application still to review by the end of 2023.
As Tropion-Breast01 is toplined positive Astra ensures the markets know that overall survival isn’t a washout.
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.
Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.